地衣芽孢杆菌联合美沙拉嗪对溃疡性结肠炎患者肠道微生态及炎性因子的调控作用

庞霄君; 孙维; 王军伟

doi:10.16766/j.cnki.issn.1674-4152.004449

地衣芽孢杆菌联合美沙拉嗪对溃疡性结肠炎患者肠道微生态及炎性因子的调控作用

doi: 10.16766/j.cnki.issn.1674-4152.004449

1.
浙江省天台县人民医院消化内科，浙江天台 317200
2.
浙江省天台县人民医院营养科，浙江天台 317200
3.
浙江省天台县人民医院感染科，浙江天台 317200

基金项目:

浙江省中医药科技计划项目 2025ZX057

详细信息

通讯作者:
庞霄君，E-mail：13968598660@163.com

中图分类号: R574.62
计量
- 文章访问数: 4
- HTML全文浏览量: 1
- PDF下载量: 1
- 被引次数: 0
出版历程
- 收稿日期: 2025-11-24

The regulatory effects of Bacillus subtilis combined with mesalazine on intestinal microecology and inflammatory factors in patients with ulcerative colitis

1.
Department of Gastroenterology, Tiantai People's Hospital of Zhejiang Province, Tiantai, Zhejiang 317200, China

摘要

摘要: 目的探讨地衣芽孢杆菌联合美沙拉嗪对溃疡性结肠炎(UC)患者肠道微生态及炎性因子的影响，为临床制定治疗方案提供借鉴。方法选择2020年5月—2025年5月浙江省天台县人民医院消化内科210例UC患者作为研究对象，采用随机数表法分成A组(105例)、B组(105例)，A组予以美沙拉嗪治疗，B组予以美沙拉嗪+地衣芽孢杆菌活菌胶囊治疗。观察2组患者临床疗效、肠道菌群菌落数、肠黏膜通透性、炎性因子及不良反应等。结果 B组总有效率[90.48%(95/105)]高于A组[79.05%(83/105), χ²=5.309，P=0.021]。B组治疗后的乳酸杆菌、双歧杆菌均高于A组(P＜0.05)，大肠杆菌低于A组(P＜0.05)；B组治疗后的二胺氧化酶(DAO)、内毒素(ETX)低于A组(P＜0.05)；B组治疗后的C反应蛋白(CRP)、白细胞介素-8(IL-8)均低于A组(P＜0.05)。2组患者不良反应发生率比较差异无统计学意义(P＞0.05)。结论地衣芽孢杆菌活菌胶囊联合美沙拉嗪治疗UC，可通过重塑肠道菌群结构、增强肠黏膜屏障完整性、下调炎症因子表达的协同作用提升疗效，且安全性良好。
- 地衣芽孢杆菌活菌胶囊 /
- 溃疡性结肠炎 /
- 肠道菌群 /
- 炎性因子 /
- 不良反应
Abstract: Objective To investigate the effects of Bacillus subtilis combined with mesalazine on the gut microbiota and inflammatory factors in patients with ulcerative colitis (UC), and to provide references to support the development of optimized clinical treatment plan formulation. Methods A total of 210 UC patients admitted to the Department of Gastroenterology, Tianta County People ' s Hospital of Zhejiang Province from May 2020 to May 2025 were randomly divided into Group A (n=105) and Group B (n=105). Group A was treated with mesalazine, while Group B was treated with mesalazine combined with Bacillus Licheniformis live bacteria capsules. The clinical efficacy, number of intestinal flora colonies, intestinal mucosal permeability, inflammatory factors, and adverse reactions were compared between the two groups. Results The total effective rate in the Group B [90.48% (95/105)] was higher than that in the Group A [79.05% (83/105), χ²=5.309, P=0.021]. After treatment, the counts of Lactobacillus and Bifidobacterium in the Group B were higher than those in the Group A (P < 0.05), whereas the count of Escherichia coli in the Group B was lower than that in the Group A (P < 0.05). The levels of diamine oxidase (DAO) and endotoxin (ETX) in the Group B after treatment were lower than those in the Group A (P < 0.05). The levels of C-reactive protein (CRP) and interleukin-8 (IL-8) in the Group B after treatment were lower than those in the Group A (P < 0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion The combination of Bacillus licheniformis live bacteria capsules and mesalazine in the treatment of UC can enhance efficacy by modulating the structure of intestinal microbiota, enhancing the integrity of intestinal mucosal barrier, and reducing the expression of inflammatory factors, while maintaining a favorable safety profile.
- Bacillus licheniformis capsule /
- Ulcerative colitis /
- Intestinal flora /
- Inflammatory factors /
- Adverse reactions
利益冲突 无

HTML全文

表 1 2组UC患者治疗前后肠道菌群菌落数比较[x±s，lg(n/g)]

Table 1. Comparison of intestinal flora colony counts before and after treatment between two groups of UC patients [x±s, lg(n/g)]

组别	例数	乳酸杆菌		双歧杆菌		大肠杆菌
组别	例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
A组	105	4.63±0.58	4.75±0.61	5.18±0.63	5.32±0.75	7.16±1.17	6.89±1.06
B组	105	4.57±0.62	5.39±0.76^b	5.21±0.74	6.14±0.83^b	7.08±1.21	6.02±0.95^b
统计量		0.724^a	42.368^c	0.316^a	45.122^c	0.487^a	38.754^c
P值		0.470	＜0.001	0.752	＜0.001	0.627	＜0.001
注：^a为t值，^c为F值；与同组治疗前比较，^bP＜0.05。

下载: 导出CSV

表 2 2组UC患者治疗前后肠黏膜通透性比较(x±s)

Table 2. Comparison of intestinal mucosal permeability before and after treatment between two groups of UC patients (x±s)

组别	例数	DAO(U/mL)		ETX(EU/mL)
组别	例数	治疗前	治疗后	治疗前	治疗后
A组	105	7.58±1.91	6.26±1.43^b	0.21±0.08	0.12±0.04^b
B组	105	7.62±1.87	5.14±1.25^b	0.22±0.06	0.09±0.02^b
统计量		0.153^a	32.691^c	1.025^a	29.875^c
P值		0.878	＜0.001	0.307	＜0.001
注：^a为t值，^c为F值；与同组治疗前比较，^bP＜0.05。

下载: 导出CSV

表 3 2组UC患者治疗前后炎性因子比较(x±s)

Table 3. Comparison of inflammatory factors before and after treatment between two groups of UC patients (x±s)

组别	例数	CRP(mg/L)		IL-8(ng/L)
组别	例数	治疗前	治疗后	治疗前	治疗后
A组	105	76.01±6.37	39.25±4.61^b	548.71±52.38	271.59±30.43^b
B组	105	74.83±5.69	35.96±3.93^b	552.42±50.59	249.07±25.41^b
统计量		1.416^a	28.453^c	0.522^a	26.917^c
P值		0.158	＜0.001	0.602	＜0.001
注：^a为t值，^c为F值；与同组治疗前比较，^bP＜0.05。

下载: 导出CSV

参考文献(21)

[1]	贾雪梅, 郭榆西, 王杰, 等. "肠道菌群-细胞焦亡"与溃疡性结肠炎"浊毒内蕴"病因病机[J]. 中国中西医结合杂志, 2024, 44(4): 475-480. JIA X M, GUO Y X, WANG J, et al. "Gut microbiota-pyroptosis" and the etiology and pathogenesis of "internal accumulation of turbidity-toxin" in ulcerative colitis[J]. Chinese Journal of Integrated Traditional and Western Medicine, 2024, 44(4): 475-480.
[2]	LE BERRE C, HONAP S, PEYRIN-BIROULET L. Ulcerative colitis[J]. Lancet, 2023, 402(10401): 571-584. doi: 10.1016/S0140-6736(23)00966-2
[3]	祁智, 庞健, 单慧明, 等. 血清IL-6, Hcy, MLR及血脂水平与溃疡性结肠炎患者的相关性分析[J]. 中国基层医药, 2025, 32(2): 239-244. QI Z, PANG J, SHAN H M, et al. Correlation of serum interleukin-6 and homocysteine levels, monocyte-to-lymphocyte ratio, and serum lipid levels with ulcerative colitis[J]. Chinese Journal of Primary Medicine and Pharmacy, 2025, 32(2): 239-244.
[4]	WANGCHUK P, YESHI K, LOUKAS A. Ulcerative colitis: clinical biomarkers, therapeutic targets, and emerging treatments[J]. Trends Pharmacol Sci, 2024, 45(10): 892-903. doi: 10.1016/j.tips.2024.08.003
[5]	李慧, 张萍, 徒文静, 等. 补蔻补虚汤治疗溃疡性结肠炎的临床效果[J]. 西部医学, 2024, 36(7): 1007-1011. LI H, ZHANG P, TU W J, et al. Clinical effect of bukoubuxu decoction on ulcerative colitis and its regulatory effect on inflammatory mediator and immune function[J]. Medical Journal of West China, 2024, 36(7): 1007-1011.
[6]	梁丽娟, 赖卫国, 朱春平, 等. 溃疡性结肠炎中肠道菌群相关治疗的研究进展[J]. 南昌大学学报(医学版), 2023, 63(4): 94-99. LIANG L J, LAI W G, ZHU C P, et al. Research Progress in Treatment of Intestinal Flora in Ulcerative Colitis[J]. Journal of Nanchang University (Medical Sciences), 2023, 63(4): 94-99.
[7]	田静, 邓莉. 地衣芽孢杆菌活菌胶囊治疗溃疡性结肠炎的临床疗效及对患者肠道黏膜通透性和肠道菌群的影响[J]. 中国免疫学杂志, 2024, 40(2): 378-382. TIAN J, DENG L. Clinical efficacy of Bacillus licheniformis viable capsules in the treatment of ulcerative colitis and its effect on intestinal mucosal permeability and intestinal flora[J]. Chinese Journal of Immunology, 2024, 40(2): 378-382.
[8]	林笑晗, 贲腾. 维得利珠单抗联合美沙拉嗪治疗活动期溃疡性结肠炎疗效观察[J]. 转化医学杂志, 2024, 13(9): 1474-1478. LIN X H, BEN T. The Efficacy of Vedolizumab Combined with Mesalazine in Active Ulcerative Colitis[J]. Translational Medicine Journal, 2024, 13(9): 1474-1478.
[9]	ABBAS A, DI FONZO D M P, WETWITTAYAKHLANG P, et al. Management of ulcerative colitis: where are we at and where are we heading?[J]. Expert Rev Gastroenterol Hepatol, 2024, 18(10): 567-574. doi: 10.1080/17474124.2024.2422370
[10]	叶梦玲, 刘阳, 汤磊磊, 等. 肠道屏障与肠道菌群在溃疡性结肠炎中的研究进展[J]. 微生物学通报, 2024, 51(9): 3384-3397. YE M L, LIU Y, TANG L L, et al. Research progress of intestinal barrier and gut microbiota in ulcerative colitis[J]. Microbiology China, 2024, 51(9): 3384-3397.
[11]	许博洋, 杨雯迪, 李伟, 等. 中西医治疗溃疡性结肠炎的比较与分析[J]. 中华全科医学, 2024, 22(10): 1640-1644, 1713. doi: 10.16766/j.cnki.issn.1674-4152.003701 XU B Y, YANG W D, LI W, et al. Comparison and analysis of traditional Chinese medicine and Western medicine in the treatment of ulcerative colitis[J]. Chinese Journal of General Practice, 2024, 22(10): 1640-1644, 1713. doi: 10.16766/j.cnki.issn.1674-4152.003701
[12]	史瑞, 李军祥, 沈洪, 等. 溃疡性结肠炎中医诊疗专家共识(2023)[J]. 中华中医药杂志, 2024, 39(1): 288-296. SHI R, LI J X, SHEN H, et al. Expert consensus on diagnosis and treatment of ulcerative colitis in traditional Chinese medicine (2023)[J]. China Journal of Traditional Chinese Medicine and Pharmacy, 2024, 39(1): 288-296.
[13]	GONZÁLEZ-LAMA Y, RICART E, CÁBEZ A, et al. Medical consultation in ulcerative colitis: key elements for improvement[J]. World J Gastroenterol, 2023, 29(6): 917-925. doi: 10.3748/wjg.v29.i6.917
[14]	张浩冉, 崔海栋, 梁国英. 生物制剂在溃疡性结肠炎治疗中应用的研究进展[J]. 国际消化病杂志, 2023, 43(4): 213-216. ZHANG H R, CUI H D, LIANG G Y. Research progress of biological agents in treatment of ulcerative colitis[J]. International Journal of Digestive Diseases, 2023, 43(4): 213-216.
[15]	LI R, YANG L. Research progress in the combined treatment of ulcerative colitis[J]. Rev Esp Enferm Dig, 2025, 117(3): 129-135.
[16]	向导, 周安付, 李艳娟, 等. 溃疡性结肠炎合并艰难梭菌感染患者肠道菌群多样性及代谢特征分析[J]. 疑难病杂志, 2023, 22(3): 300-304. XIANG D, ZHOU A F, LI Y J, et al. Analysis of intestinal flora diversity and metabolic characteristics in patients with ulcerative colitis complicated with clostridium difficile infection[J]. Chinese Journal of Difficult and Complicated Cases, 2023, 22(3): 300-304.
[17]	谭书法, 张磊昌, 高强强, 等. 生物制剂和小分子药物治疗溃疡性结肠炎有效性与安全性的网状meta分析[J]. 中国全科医学, 2024, 27(17): 2155-2166. TAN S F, ZHANG L C, GAO Q Q, et al. Efficacy and Safety of Biologics and Small Molecule Drugs in the Treatment of Ulcerative Colitis: a Network Meta-analysis[J]. Chinese General Practice, 2024, 27(17): 2155-2166.
[18]	ROSSIER L, MATTER C. Overview and update on treatment in ulcerative colitis[J]. Ther Umsch, 2023, 80(9): 386-392.
[19]	杨静芳, 王彬彬, 石向阳. 维生素D辅助微生态制剂、美沙拉嗪治疗溃疡性结肠炎的效果研究[J]. 新疆医科大学学报, 2025, 48(1): 60-65. YANG J F, WANG B B, SHI X Y. Effect of vitamin D assisted microecological preparations and mesalazine in the treatment of ulcerative colitis[J]. Journal of Xinjiang Medical University, 2025, 48(1): 60-65.
[20]	NAGARAJ T, SHINN J, DE FELICE K. A practical guide to selecting and using new ulcerative colitis therapies[J]. Curr Opin Gastroenterol, 2024, 40(4): 235-242. doi: 10.1097/MOG.0000000000001023
[21]	王泽惠, 陈天, 彭云花, 等. 清热愈疡汤治疗溃疡性结肠炎对患者肠道菌群紊乱和改善炎症效果的组方分析[J]. 吉林中医药, 2024, 44(4): 448-452. WANG Z H, CHEN T, PENG Y H, et al. Analysis of the effects of Qingre Yuyang decoction on intestinal flora disturbance and inflammation improvement in patients with ulcerative colitis[J]. Jilin Journal of Chinese Medicine, 2024, 44(4): 448-452.